mani
aspect
viral
infect
dynam
inhibit
govern
stochast
process
singlecel
analysi
provid
inform
approach
use
popul
averag
develop
microfluid
devic
compos
well
well
contain
microstructur
captur
singl
infect
cell
replic
enteroviru
express
fluoresc
report
protein
use
system
character
enteroviru
inhibitor
distinct
mechan
action
singlecel
analysi
reveal
class
inhibitor
interfer
viral
infect
cycl
manner
distinguish
princip
compon
analysi
singlecel
analysi
antivir
candid
reveal
efficaci
also
facilit
cluster
drug
mechan
action
provid
indic
eas
resist
develop
past
decad
world
wit
outbreak
myriad
rna
virus
includ
west
nile
viru
sever
acut
respiratori
syndrom
coronaviru
chikungunya
viru
ebola
viru
zika
viru
recent
polioviru
pv
relat
virus
enteroviru
enteroviru
unfortun
viral
emerg
outpac
discoveri
develop
compound
capabl
treat
pathogen
sporad
outbreak
come
go
may
never
come
develop
broadspectrum
therapeut
exhibit
high
barrier
resist
would
greatest
valu
unbias
screen
chemic
librari
antivir
agent
use
cellbas
assay
problem
identifi
activ
compound
high
potenc
howev
identifi
target
predict
likelihood
evolut
resist
gener
take
year
effort
follow
compound
discoveri
part
studi
evalu
pv
infect
dynam
singlecel
level
observ
chaintermin
antivir
ribonucleotid
select
elimin
mostfit
member
viral
popul
class
antivir
agent
alway
tout
high
barrier
resist
typic
explan
high
barrier
amino
acid
substitut
activ
site
viral
rna
polymeras
confer
resist
antivir
ribonucleosid
also
impair
specif
andor
effici
incorpor
natur
ribonucleotid
elimin
mostfit
member
viral
popul
antivir
agent
requir
resist
emerg
surviv
lowfit
member
popul
would
ultim
requir
restor
fit
popul
surviv
myriad
mechan
host
restrict
restor
fit
may
insurmount
barrier
preclud
develop
resist
chaintermin
antivir
ribonucleotid
studi
design
determin
extent
singlecel
analysi
antivir
agent
contribut
understand
antivir
therapeut
rel
tradit
approach
describ
microfluid
devic
use
produc
complet
doserespons
curv
use
devic
compar
three
mechanist
distinct
class
antivir
agent
pv
polymeras
inhibitor
pv
proteas
inhibitor
rupintrivir
two
heat
shock
protein
inhibitor
geldanamycin
ga
ganetespib
gs
find
singlecel
analysi
distinguish
class
inhibitor
suggest
addit
singlecel
analysi
exist
paradigm
preclin
develop
antivir
therapi
may
potenti
identifi
lead
limit
potenti
develop
resist
initi
foray
singlecel
analysi
pv
infect
dynam
use
cell
densiti
control
singlecel
occup
well
microfluid
devic
mean
practic
well
empti
reduc
number
event
monitor
mere
factor
two
take
us
number
event
requir
statist
analysi
data
acquisit
doserespons
curv
therefor
imposs
use
firstgener
devic
address
problem
creat
multilay
devic
previous
describ
fig
ad
trap
structur
channel
layer
devic
fig
fig
posit
trap
structur
guid
simul
fig
lead
placement
trap
structur
rear
wall
well
fig
devic
contain
five
independ
zone
contain
well
total
well
devic
mount
easili
stage
microscop
fig
devic
cross
section
shown
fig
singlecel
occup
devic
sensit
width
channel
use
load
fig
cell
densiti
fig
maximum
occup
near
fig
fig
condit
inhibitor
reduc
infect
infect
cell
observ
use
devic
number
event
enough
statist
analysi
viral
polymeras
repres
wellestablish
target
antivir
therapeut
exampl
cocktail
use
treat
human
immunodefici
viru
infect
hepat
c
viru
hcv
infect
includ
synthet
nucleosid
analog
target
revers
transcriptas
rnadepend
rna
polymeras
rdrp
respect
nonoblig
chaintermin
antivir
ribonucleosid
prototyp
hcv
rdrp
inhibitor
sofosbuvir
relat
compound
previou
studi
evalu
infect
surviv
treatment
present
concentr
reduc
number
infect
median
inhibitori
concentr
ic
surpris
observ
select
ablat
cell
infect
viru
variant
capabl
fastest
rate
replic
highest
yield
replic
rna
experi
suffer
inabl
evalu
concentr
drug
higher
valu
ic
use
valid
new
devic
experi
report
herein
pretreat
hela
cell
drug
hour
infect
cell
chip
pv
engin
express
enhanc
green
fluoresc
protein
pvegfp
multipl
infect
moi
plaqueform
unit
pfu
per
cell
pellet
wash
cell
remov
free
viru
suspend
cell
densiti
cellsml
drugcontain
medium
load
microfluid
devic
well
monitor
egfp
fluoresc
everi
min
period
give
rise
popul
time
cours
exhibit
substanti
betweencel
variabl
fig
plot
percentag
infect
green
gfpposit
cell
function
drug
concentr
fit
hyperbola
obtain
valu
ic
valu
case
concentr
greater
exhibit
toxic
therefor
data
fit
hyperbola
fig
clear
experi
howev
approach
sensit
enough
acquir
data
complet
doserespons
analysi
fig
major
advantag
singlecel
platform
effect
drug
viabl
popul
determin
analyz
singlecel
data
use
five
phenomenolog
paramet
extract
time
cours
fig
paramet
maximum
fluoresc
observ
correl
yield
genom
rna
slope
time
halfmaximum
fluoresc
correl
replic
speed
infect
time
first
approxim
time
take
infect
go
start
finish
akin
viru
gener
time
start
point
earliest
time
fluoresc
detect
midpoint
time
halfmaximum
fluoresc
analysi
lead
collect
data
point
paramet
valu
measur
cell
instead
display
primari
data
scatter
plot
fig
e
display
analyz
curv
deriv
first
deriv
cumul
distribut
function
raw
data
fig
statist
analysi
use
unpair
twotail
test
determin
signific
differ
exist
mean
given
paramet
two
experiment
condit
experi
area
curv
defin
distribut
normal
one
eas
comparison
attempt
interpret
differ
fine
structur
distribut
use
data
analysi
pipelin
evalu
outcom
absenc
presenc
observ
statist
signific
differ
mean
valu
maximum
fig
slope
fig
paramet
without
statist
signific
chang
mean
valu
remain
paramet
fig
h
j
tabul
data
statist
analysi
experi
provid
tabl
observ
reproduc
outcom
present
us
previous
use
firstgener
devic
mean
valu
maximum
slope
paramet
reduc
substanti
presenc
observ
betweencel
variabl
respons
treatment
attribut
multipl
factor
includ
speed
andor
fidel
viral
polymeras
capac
nucleosid
convert
nucleosid
triphosph
ntp
among
possibl
observ
subset
viral
popul
sensit
unexpect
could
easili
ration
notion
increas
replic
effici
correl
increas
incorpor
effici
inhibitor
viral
enzym
exhibit
select
proteas
retrovirus
positivesens
rna
virus
respons
polyprotein
process
repres
second
categori
wellestablish
antivir
therapeut
use
cocktail
treat
hiv
hcv
respect
inhibitor
picornavir
proteas
respons
polyprotein
process
pursu
mani
year
studi
select
rupintrivir
target
proteas
activ
three
type
pv
well
ev
measur
impact
rupintrivir
establish
pv
infect
hela
cell
fig
ic
valu
nm
agre
valu
nm
measur
use
convent
plaqu
assay
analyz
singlecel
data
obtain
concentr
tabl
outcom
rupintrivir
distinct
conclud
antivir
agent
interfer
viral
popul
manner
stage
lifecycl
reflect
paramet
determin
monitor
kinet
fluoresc
produc
gfp
report
viru
compound
antagon
function
cellular
chaperon
repres
emerg
class
anticanc
antivir
therapeut
chaperon
famili
requir
cell
grow
fast
andor
produc
high
level
protein
observ
cancer
cell
virusinfect
cell
semin
studi
frydman
andino
laboratori
demonstr
clear
essenti
role
product
infecti
pv
virion
howev
everi
step
viru
lifecycl
suggest
target
virus
outsid
picornaviru
famili
consid
benefit
target
antivir
therapeut
cellular
protein
likelihood
evolut
resist
minim
use
ga
potent
inhibitor
nanomolar
rang
activ
pv
presenc
ga
reduc
number
infect
establish
ic
valu
nm
fig
earlier
studi
observ
impact
ga
prior
viru
assembl
howev
possibl
reduct
magnitud
shown
would
conceal
experiment
error
infect
monitor
egfp
requir
viru
entri
genom
replic
genom
translat
interfer
step
would
lead
reduct
number
egfpposit
cell
clear
howev
translat
fold
egfp
alter
presenc
highest
concentr
ga
use
experi
fig
analysi
singlecel
data
present
tabl
mean
distribut
valu
maximum
paramet
chang
presenc
ga
fig
contrast
inhibitor
target
viral
protein
observ
statist
signific
differ
distribut
valu
infect
time
paramet
concentr
depend
fig
statist
signific
differ
mean
distribut
remain
paramet
observ
concentr
correspond
ic
fig
c
e
f
third
signatur
antivir
action
therefor
reveal
ga
given
interest
use
inhibitor
therapeut
cancer
varieti
compound
exist
exampl
gs
inhibitor
differ
ga
substanti
chemic
structur
compar
inset
fig
fig
thought
mechan
action
use
gs
provid
import
test
capac
singlecel
analysi
reveal
common
signatur
compound
common
mechan
contrast
observ
ga
gs
reduc
number
infect
establish
ic
nm
due
higher
affin
analysi
singlecel
data
present
tabl
impact
gs
five
phenomenolog
paramet
observ
ga
fig
case
clear
mechanist
ident
compound
yield
ident
signatur
singlecel
level
longterm
use
antivir
therapi
determin
part
time
requir
resist
mutant
emerg
one
approach
delay
even
elimin
emerg
drugresist
mutant
use
antivir
combin
often
evalu
abil
two
drug
exhibit
greater
efficaci
synergi
prevent
infect
combin
observ
either
drug
use
alon
evalu
abil
synerg
ga
treat
cell
concentr
one
ic
valu
fig
absenc
drug
cell
devic
infect
number
reduc
presenc
ga
combin
thereof
respect
basi
observ
alon
conclus
would
combin
antivir
agent
even
addit
analysi
entir
singlecel
dataset
present
tabl
exhibit
substanti
antivir
effect
rel
dimethyl
sulfoxid
dmso
control
compar
combin
alon
observ
statist
signific
differ
paramet
fig
b
f
singlecel
analysi
therefor
abil
reveal
efficaci
drug
combin
mask
popul
level
perform
compar
experi
gs
reach
conclus
fig
tabl
evalu
three
class
antipv
drug
reveal
three
uniqu
signatur
base
chang
phenomenolog
paramet
use
describ
infect
dynam
fig
reason
princip
compon
analysi
pca
might
provid
even
robust
approach
compar
dataset
use
five
paramet
shown
fig
pca
resolv
class
inhibitor
well
outcom
absenc
drug
mechanist
relat
chemic
distinct
inhibitor
cluster
pca
see
ga
gs
fig
evalu
antivir
drug
combin
context
pca
space
fig
addit
combin
defin
vector
bisect
parallelogram
defin
experi
absenc
either
drug
control
experi
presenc
drug
alon
fig
combin
synergist
posit
indic
combin
delay
start
point
retard
infect
time
conclud
singlecel
analysi
antivir
therapeut
provid
inform
efficaci
drug
also
inform
mechan
action
synergi
combin
antivir
therapeut
experiment
paradigm
transform
impact
drug
develop
process
era
singlecel
virolog
begun
infect
outcom
cell
determin
part
stochast
process
exampl
presenc
abund
viral
restrict
factor
viral
replic
promot
factor
host
larg
govern
stochast
gene
express
result
substanti
betweencel
variat
exist
quantifi
paramet
infect
underappreci
consequ
behavior
system
nonselfaverag
natur
system
mean
popul
averag
singlecel
paramet
almost
certainli
fail
repres
dynam
within
singl
cell
practic
complic
aris
phenomenon
chang
averag
kinet
observ
growth
curv
viru
caus
perturb
eg
exposur
antivir
therapeut
inform
accur
step
viral
lifecycl
affect
perturb
perspect
mind
surpris
previou
evalu
antivir
ribonucleotid
use
singlecel
approach
reveal
unexpect
find
mostfit
member
viral
popul
suscept
class
compound
observ
left
one
major
unresolv
question
effect
antivir
therapeut
target
subpopul
virus
uniqu
signatur
exist
distinct
mechanist
class
antivir
therapeut
address
question
central
object
studi
firstgener
microfluid
devic
onchip
investig
viral
infect
dynam
reli
cell
densiti
mechan
achiev
isol
singl
cell
well
devic
approach
leav
well
devic
empti
redesign
devic
add
physic
celltrap
structur
well
outcom
abil
achiev
singlecel
occup
well
devic
fig
fig
enhanc
occup
enabl
complet
character
antivir
therapeut
permit
acquisit
complet
doserespons
curv
eg
fig
three
class
antivir
therapeut
chosen
target
viral
polymeras
fig
viral
proteas
rupintrivir
fig
host
factor
ga
fig
gs
fig
data
analysi
pipelin
emphas
five
phenomenolog
paramet
correl
tradit
paramet
assess
viral
lifecycl
major
find
studi
class
antivir
therapeut
exhibit
uniqu
signatur
respect
five
phenomenolog
paramet
measur
use
absolut
valu
differ
paramet
presenc
absenc
antivir
agent
visual
signatur
antivir
agent
compar
one
antivir
agent
anoth
fig
possibl
use
pca
stratifi
differ
therapeut
class
fig
ga
gs
overlap
pca
despit
substanti
differ
structur
efficaci
fig
drug
combin
fail
affect
establish
infect
exhibit
synergi
singlecel
paramet
monitor
fig
observ
previous
virus
highest
yield
maximum
fastest
rate
replic
slope
sensit
fig
effici
polymeras
like
requir
replic
fast
highest
level
polymeras
might
expect
use
antivir
nucleotid
better
lead
extinct
popul
virus
member
viral
popul
sensit
rupintrivir
fig
case
concentr
equival
lower
ic
bind
driven
concentr
proteas
target
would
highest
cell
replic
fastest
highest
level
ga
affect
subset
rupintrivirsensit
member
fast
rate
replic
fig
observ
quit
interest
fast
rate
replic
assay
mean
fast
rate
translat
produc
gfp
chaperon
like
would
expect
use
condit
compar
analysi
use
start
point
infect
time
provid
even
greater
distinct
three
class
antivir
agent
studi
herein
fig
e
g
noteworthi
observ
rupintrivir
retard
time
took
establish
infect
complet
replic
fig
observ
may
reflect
role
proteas
promot
replic
cleav
cellular
antagonist
viru
lifecycl
studi
among
first
analyz
rang
antivir
therapeut
viral
infect
dynam
singlecel
level
resolut
afford
approach
unpreced
compar
cellbas
approach
provid
measur
efficaci
given
substanti
effort
requir
go
compound
mechan
use
tradit
experiment
paradigm
abil
singlecel
analysi
inform
mechan
make
approach
welcom
addit
drug
discoveri
develop
toolbox
uncommon
analog
synthes
drug
develop
process
lose
specif
even
function
differ
mechan
action
singlecel
analysi
potenti
reveal
chang
start
analysi
instead
much
much
later
develop
process
last
although
use
antivir
agent
demonstr
power
singlecel
analysi
use
technolog
approach
applic
discoveri
develop
class
therapeut
assess
cell
cultur
hela
hela
cell
obtain
american
type
cultur
collect
maintain
dulbecco
modifi
eagl
life
technolog
supplement
fetal
bovin
serum
atlanta
biolog
penicillinstreptomycin
iuml
corn
humidifi
atmospher
air
co
gener
enhanc
green
fluoresc
protein
egfp
tag
pv
use
work
pmoegfppvwt
plasmid
linear
apa
purifi
use
qiaex
ii
gel
extract
kit
qiagen
netherland
linear
plasmid
templat
viral
rna
transcrib
hour
reaction
medium
contain
mm
hepe
ph
mm
magnesium
acet
mm
dithiothreitol
mm
spermidin
mm
ntp
linear
dna
rna
polymeras
remov
magnesium
pyrophosph
mixtur
centrifug
min
rna
concentr
measur
scan
gel
fluoresc
mode
typhoon
scanner
promega
usa
viral
rna
use
transfect
hela
cell
cultur
electropor
viru
harvest
three
repeat
freezethaw
cycl
centrifug
rpm
min
suspend
purif
supernat
mix
volum
polyethylen
glycol
molecular
weight
nacl
solut
incub
overnight
centrifug
min
pellet
resuspend
phosphatebuff
salin
pb
filter
centricon
emd
millipor
usa
plaqu
assay
perform
determin
viru
titer
dmso
rupintrivir
purchas
sigma
chemic
co
st
loui
mo
usa
obtain
carbosynth
limit
compton
berkshir
uk
solut
ga
gs
dmso
provid
x
zhang
depart
chemistri
pennsylvania
state
univers
j
frydman
depart
biolog
stanford
univers
respect
antivir
compound
predilut
dmso
use
drug
group
volum
dmso
spike
cultur
medium
microfluid
layer
fabric
polydimethylsiloxan
pdm
ge
standard
soft
lithographi
techniqu
mold
fabric
coat
photoresist
desir
thick
silicon
wafer
photolithograph
pattern
fig
premix
pdm
prepolym
cure
agent
ratio
pour
onto
mold
valv
layer
cure
premix
pdm
prepolym
cure
agent
ratio
spin
coat
mold
channel
layer
rpm
min
incub
min
valv
layer
releas
mold
place
channel
layer
align
assembl
bake
overnight
effici
bond
assembl
bond
align
microwel
layer
cure
premix
pdm
prepolym
cure
agent
ratio
bake
overnight
obtain
devic
bond
glass
slide
prevent
deform
appli
pressur
valv
group
hela
cell
cultur
drugcontain
medium
hour
cell
centrifug
resuspend
pb
mix
egfppv
moi
pfu
per
cell
shake
rpm
min
cell
centrifug
resuspend
media
correspond
treatment
phd
ultra
syring
pump
harvard
apparatu
cell
suspens
infus
inlet
microfluid
devic
trap
singl
cell
min
pressur
psi
appli
valv
isol
microwel
devic
place
chamber
stage
top
wskm
incub
system
tokai
japan
adapt
nikon
eclips
ti
invert
microscop
nikon
japan
equip
proscan
ii
motor
flat
top
stage
prior
scientif
usa
setup
brightfield
fluoresc
imag
microwel
automat
acquir
everi
min
hour
postinfect
imag
microwel
includ
plan
apochromat
lambda
object
hamamatsu
camera
infect
uninfect
cell
count
manual
calcul
percentag
infect
custom
matlab
script
use
extract
fluoresc
intens
background
intens
microwel
fluoresc
imag
fluoresc
intens
background
background
calcul
repres
rel
intens
meanwhil
well
contain
two
infect
cell
show
autofluoresc
outoffocu
signal
manual
exclud
result
fluoresc
intens
infect
singl
cell
time
could
obtain
custom
packag
r
maximum
slope
infect
time
start
point
midpoint
deriv
data
curv
describ
previous
comparison
differ
experi
intens
normal
uniform
mean
valu
maximum
drug
group
arbitrari
unit
work
visual
distribut
fig
elsewher
manuscript
calcul
cumul
distribut
function
raw
data
calcul
first
deriv
smooth
use
savitzkygolay
smooth
area
curv
normal
experiment
data
obtain
triplic
present
mean
sd
unless
otherwis
mention
unpair
twotail
test
use
determin
signific
differ
exist
mean
given
paramet
two
experiment
condit
statist
analysi
perform
use
originpro
softwar
supplementari
materi
articl
avail
http
advancessciencemagorgcgi
fig
microfluid
devic
contain
celltrap
microstructur
highthroughput
analysi
singlecel
infect
tabl
mean
sd
p
valu
group
experi
tabl
mean
sd
p
valu
group
rupintrivir
experi
tabl
mean
sd
p
valu
group
experi
inhibitor
tabl
mean
sd
p
valu
group
antivir
synergi
experi
viewrequest
protocol
paper
bioprotocol
